Medicines access explained
The term is a starting point.
The arrangement matters.
Make sense of expanded access, early access, named patient programmes and managed access before deciding what to ask next.
Similar words can describe different arrangements.
Expanded access, early access, named patient programmes and managed access are often discussed together. The useful question is what arrangement is being proposed, for which medicine, in which country and under whose responsibility.
An acronym does not establish an access route. The same label can carry different meanings across countries and organisations. Start with the purpose, then check the applicable rules and the responsible company’s published policy.
What the terms can mean
- Expanded access programme / EAP
- In the US, FDA uses expanded access for potential treatment with an investigational product outside a clinical trial when specified conditions are met. A clinical trial and expanded access serve different purposes. The label alone does not establish availability or eligibility. Read FDA’s explanation.
- Early access programme / EAP
- Often used as an umbrella description in industry. It can refer to different country arrangements; it is not one globally transferable legal route. Ask which national process the proposed programme actually uses.
- Named patient programme / NPP
- Describes arrangements centred on an individual patient. Requirements depend on the country and product status. EMA distinguishes named-patient treatment from the compassionate-use programmes it discusses under the EU framework. Read EMA’s distinction.
- Compassionate use
- FDA sometimes uses this term alongside expanded access. In Europe, the applicable national arrangements need to be checked. Do not assume the US and European descriptions carry identical requirements.
- Managed access programme / MAP
- Used in different ways. NICE’s managed-access context includes access while specified evidence uncertainty is addressed; industry may use the phrase differently. Clarify whether the discussion concerns a pre-authorisation route, a reimbursement arrangement or programme administration. See NICE’s managed-access information.
- Post-trial access / PTA
- Concerns arrangements after participation in a trial. The commitments, potential route, responsibilities and continuing supply need to be considered together. It is not established simply by renaming a trial supply arrangement. Explore post-trial planning.
Five questions make the discussion more useful.
- Which country and product status?Local requirements and whether a medicine is authorised for the proposed use matter.
- Who is making the request?Establish whether the process requires a treating professional, an organisation or another specified party.
- Who decides and who supplies?Identify the responsible company, programme and healthcare team; keep their roles distinct.
- What changes after a trial or country transition?Check the new arrangements before assuming that an existing supply can continue.
- Where is the current official process?Use the published company or programme channel and the relevant regulator’s guidance.
Designing a programme? Start with the decisions.
IAE helps commissioning organisations assess route options, programme responsibilities, evidence needs and delivery arrangements. Bring the situation and the decision you face; a complete brief is not needed.
Prepared by IAE Consults · Sources checked 26 September 2026. General orientation, not a country-by-country eligibility assessment. Recheck the applicable official source before relying on a process.
Leave with a clearer next question.
Use the official company or programme channel for a treatment-access request, with your healthcare professional wherever required. IAE can help explain a published process or unfamiliar term in general.
Find official sourcesAsk a general process questionIAE is independent of pharmaceutical companies, biotechnology companies and service providers. We do not receive or progress individual treatment-access applications.